Table 4.
Univariate and multivariable Cox regression models addressing the prediction of cancer‐specific survival after radical cystectomy for urothelial carcinoma of the bladder
| Variables | Univariate analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | P‐value | Hazard ratio | 95% CI | P‐value | |
| Age at RC (continous) | 1.03 | 1.01–1.05 | 0.002 | 1.01 | 0.99–1.033 | 0.206 |
| Gender (reference: male) | 1.32 | 0.89–1.96 | 0.163 | — | — | — |
| Presence of sarcopenia (reference: absence) | 1.49 | 1.07–2.07 | 0.018 | 1.42 | 1.00–2.02 | 0.048 |
| pT stage | ||||||
| pT2 (reference: ≤pT1) | 1.64 | 0.80–3.35 | 0.184 | 1.33 | 0.64–2.77 | 0.442 |
| pT3 (reference: ≤pT1) | 6.71 | 3.46–13.02 | <0.001 | 3.54 | 1.73–7.24 | 0.001 |
| pT4 (reference: ≤pT1) | 8.57 | 4.20–17.46 | <0.001 | 3.20 | 1.41–7.27 | 0.005 |
| Presence of CIS (reference: absence) | 0.78 | 0.55–1.11 | 0.164 | — | — | — |
| Presence of LVI (reference: absence) | 3.72 | 2.65–5.22 | <0.001 | 1.81 | 1.20–2.73 | 0.005 |
| Positive soft tissue surgical margin (reference: negative) | 5.89 | 3.92–8.83 | <0.001 | 3.24 | 2.01–5.23 | <0.001 |
| pN stage | ||||||
| pN+ (reference: pN0) | 4.14 | 2.95–5.81 | <0.001 | 1.79 | 1.19–2.70 | 0.005 |
| pNx (reference: pN0) | 2.57 | 1.12–5.91 | 0.026 | 1.75 | 0.74–4.15 | 0.202 |
| ACE‐27 | ||||||
| ACE‐27: 1 (reference: ACE‐27 0) | 1.15 | 0.70–1.89 | 0.588 | 1.13 | 0.68–1.89 | 0.639 |
| ACE‐27: 2 (reference: ACE‐27 0) | 1.34 | 0.82–2.20 | 0.249 | 1.49 | 0.90–2.50 | 0.130 |
| ACE‐27: 3 (reference: ACE‐27 0) | 1.74 | 1.04–2.92 | 0.036 | 1.81 | 1.03–3.17 | 0.039 |
| Adjuvant chemotherapy (reference: not administered) | 2.72 | 1.87–3.94 | <0.001 | 1.11 | 0.70–1.75 | 0.67 |
| Body mass index | ||||||
| Underweight (reference: normal weight) | 0.85 | 0.59–1.24 | 0.394 | — | — | — |
| Overweight (reference: normal weight) | 0.75 | 0.47–1.19 | 0.221 | — | — | — |
| Obese (reference: normal weight) | 0.79 | 0.34–1.84 | 0.587 | — | — | — |
CI, confidence interval; RC, radical cystectomy; CIS, carcinoma in situ; LVI, lymphovascular invasion; ACE‐27, Adult Comorbidity Evaluation 27; BMI, body mass index.